Lung Cancer in Practice

This item requires a subscription.

Patient selection for chemotherapy
LCIP, Volume 5, Number 3.

Lung cancer (LC) is the leading cause of cancer death in the UK and the USA. At least 70% of patients with LC present with locally advanced or metastatic disease at the time of diagnosis. Despite the major improvements in the treatment of LC over the past decades, the outlook for these patients is dismal, with a five-year survival of only 7%. Chemotherapy (CT) is of proven benefit in the management of patients with both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In NSCLC, while surgery is the treatment modality that offers the best chance of cure, CT has a role in the neo-adjuvant, adjuvant, radical, and palliative settings. In SCLC patients, in contrast, systemic treatment is the key modality.

To view this item, select one of the options below:

	Purchase access
	In order to view articles you will need to pay a subscription for either 24-hour or annual access. You can view all articles on this site during the subscription period. Please click here to subscribe.

	Sign in
	If you are already have a subscription, please sign in here.
	email address
	Password
	Forgotten your password?

	Important
	All the articles are in PDF format.
	To view the articles you will need Adobe Acrobat Reader.
	To download a copy, free of charge, please click here.

	Help
	If you need help accessing this site, please click here.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Lung Cancer in Practice is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk